Cargando…
A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R‐CHOP‐treated diffuse large B‐cell lymphoma (DLBCL). To estimate the predictive values of PET/CT quantitative parameters and three prognostic models consisting of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718622/ https://www.ncbi.nlm.nih.gov/pubmed/31343111 http://dx.doi.org/10.1002/cam4.2284 |
_version_ | 1783447758886141952 |
---|---|
author | Zhang, Yi‐Yang Song, Le Zhao, Mei‐Xin Hu, Kai |
author_facet | Zhang, Yi‐Yang Song, Le Zhao, Mei‐Xin Hu, Kai |
author_sort | Zhang, Yi‐Yang |
collection | PubMed |
description | In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R‐CHOP‐treated diffuse large B‐cell lymphoma (DLBCL). To estimate the predictive values of PET/CT quantitative parameters and three prognostic models consisting of baseline and interim parameters for three‐year progression‐free survival (PFS), we conducted an analysis of 85 patients in China with DLBCL underwent baseline and interim PET/CT scans and treated at the Department of Hematology of Peking University Third Hospital from November 2012 to November 2017. The PET/CT parameters, viz. the baseline and interim values of standardized uptake value (SUV(max)), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG), and their rates of change, were analyzed by a receiver operating characteristics curve, Kaplan‐Meier analysis, and log‐rank test. Besides, the National Comprehensive Cancer Network International Prognostic Index (NCCN‐IPI) was also included in the multivariate Cox hazards model. Owing to the strong correlation between TMTV and TLG at baseline and interim (Pearson's correlation coefficient, r = 0.823, P‐value = 0.000, and 0.988, P‐value = 0.000, respectively), only TLG was included in the multivariate Cox hazards model, where TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% showed predictive value independently (HR = 10.42, 95% CI 2.35‐46.30, P = 0.002, and HR = 4.86, 95% CI 1.27‐18.54, P = 0.021, respectively). Replacing TLG in the equation, TMTV(0) and TMTV(1) both showed significantly predictive abilities like TLG (HR = 8.22, 95% CI 1.86‐32.24, P = 0.005, and HR = 2.96, 95% CI 1.16‐7.54, P = 0.023, respectively). After dichotomy, NCCN‐IPI also gave a significant performance (P = 0.035 and P = 0.010, respectively, in TLG and TMTV models). The baseline variables, that is, TMTV(0), TLG(0) and dichotomized NCCN‐IPI, and the interim variables TMTV(1) and %ΔSUV(max), presented independent prognostic value for PFS. In prognostic model 2 (TLG(0) + %ΔSUV(max)), the group with TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% recognized 19 (82.6%) of the relapse or progression events, which showed the best screening ability among three models consisting of baseline and interim PET/CT parameters. |
format | Online Article Text |
id | pubmed-6718622 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67186222019-09-06 A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max) Zhang, Yi‐Yang Song, Le Zhao, Mei‐Xin Hu, Kai Cancer Med Clinical Cancer Research In the era of rituximab, the International Prognostic Index (IPI) has been inefficient in initial risk stratification for patients with R‐CHOP‐treated diffuse large B‐cell lymphoma (DLBCL). To estimate the predictive values of PET/CT quantitative parameters and three prognostic models consisting of baseline and interim parameters for three‐year progression‐free survival (PFS), we conducted an analysis of 85 patients in China with DLBCL underwent baseline and interim PET/CT scans and treated at the Department of Hematology of Peking University Third Hospital from November 2012 to November 2017. The PET/CT parameters, viz. the baseline and interim values of standardized uptake value (SUV(max)), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG), and their rates of change, were analyzed by a receiver operating characteristics curve, Kaplan‐Meier analysis, and log‐rank test. Besides, the National Comprehensive Cancer Network International Prognostic Index (NCCN‐IPI) was also included in the multivariate Cox hazards model. Owing to the strong correlation between TMTV and TLG at baseline and interim (Pearson's correlation coefficient, r = 0.823, P‐value = 0.000, and 0.988, P‐value = 0.000, respectively), only TLG was included in the multivariate Cox hazards model, where TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% showed predictive value independently (HR = 10.42, 95% CI 2.35‐46.30, P = 0.002, and HR = 4.86, 95% CI 1.27‐18.54, P = 0.021, respectively). Replacing TLG in the equation, TMTV(0) and TMTV(1) both showed significantly predictive abilities like TLG (HR = 8.22, 95% CI 1.86‐32.24, P = 0.005, and HR = 2.96, 95% CI 1.16‐7.54, P = 0.023, respectively). After dichotomy, NCCN‐IPI also gave a significant performance (P = 0.035 and P = 0.010, respectively, in TLG and TMTV models). The baseline variables, that is, TMTV(0), TLG(0) and dichotomized NCCN‐IPI, and the interim variables TMTV(1) and %ΔSUV(max), presented independent prognostic value for PFS. In prognostic model 2 (TLG(0) + %ΔSUV(max)), the group with TLG(0) > 1036.61 g and %ΔSUV(max) < 86.02% recognized 19 (82.6%) of the relapse or progression events, which showed the best screening ability among three models consisting of baseline and interim PET/CT parameters. John Wiley and Sons Inc. 2019-07-25 /pmc/articles/PMC6718622/ /pubmed/31343111 http://dx.doi.org/10.1002/cam4.2284 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Zhang, Yi‐Yang Song, Le Zhao, Mei‐Xin Hu, Kai A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max) |
title | A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
|
title_full | A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
|
title_fullStr | A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
|
title_full_unstemmed | A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
|
title_short | A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
|
title_sort | better prediction of progression‐free survival in diffuse large b‐cell lymphoma by a prognostic model consisting of baseline tlg and %δsuv(max) |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718622/ https://www.ncbi.nlm.nih.gov/pubmed/31343111 http://dx.doi.org/10.1002/cam4.2284 |
work_keys_str_mv | AT zhangyiyang abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax AT songle abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax AT zhaomeixin abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax AT hukai abetterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax AT zhangyiyang betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax AT songle betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax AT zhaomeixin betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax AT hukai betterpredictionofprogressionfreesurvivalindiffuselargebcelllymphomabyaprognosticmodelconsistingofbaselinetlganddsuvmax |